{
  "ticker": "PTX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02965979",
  "id": "02965979",
  "pages": 40,
  "price_sensitive": false,
  "date": "20250704",
  "time": "0918",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250704/pdf/06lgflgm2r2k6h.pdf",
  "summary": "### **Material Information Summary (Prescient Therapeutics SPP Announcement)**  \n\n#### **Capital Raising Announcement**  \n- **Type**: Share Purchase Plan (SPP)  \n- **Target Amount**: AUD $7 million  \n- **Offer Price**: AUD $0.040/share (16.7% discount to 15-day VWAP as of 30 June 2025)  \n- **Use of Proceeds**: Fund Phase 2 clinical development of PTX-100 (targeted cancer therapy) + working capital.  \n- **SPP Close Date**: 15 July 2025, 5PM AEST.  \n\n#### **Key Clinical Highlights**  \n- **PTX-100 (Phase 1b)**:  \n  - 45% response rate, 64% clinical benefit rate in T-cell lymphomas (TCL).  \n  - FDA Fast Track + Orphan Drug Designation for CTCL (US$605M market by 2030).  \n- **Phase 2a Trial**: Enrolling 40 patients (Australia, US, EU); potential Phase 2b registration study.  \n\n#### **Upcoming Catalyst**  \n- **EU Orphan Designation**: Expected Q3 2025.  \n\n*No other material trading/capital structure impacts identified.*",
  "usage": {
    "prompt_tokens": 6822,
    "completion_tokens": 264,
    "total_tokens": 7086,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-03T23:33:38.144005"
}